Telomir Pharmaceuticals, Inc. Payments of Debt Issuance Costs
Telomir Pharmaceuticals, Inc. (TELO) reported Payments of Debt Issuance Costs of $255.97 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-02-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2025-02-04
- Telomir Pharmaceuticals, Inc. payments of debt issuance costs for the quarter ending 2023-12-31 was $200.39K.
- Telomir Pharmaceuticals, Inc. payments of debt issuance costs for the quarter ending 2023-09-30 was $21.46K.
- Telomir Pharmaceuticals, Inc. payments of debt issuance costs for fiscal 2023 was $255.97K.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2023-12-31 | $200.39K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-04 | $221.84K derived: sum of 2 quarters · filed 2025-02-04 | $255.97K 10-K · filed 2025-02-04 | |
| 2023-09-30 | $21.46K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $55.58K 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $34.13K 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |